First transfemoral mitral valve repair system with atraumatic anchoring
coramaze is developing the mitramaze® valve repair system – a novel concept for transcatheter valve repair, intended for treatment of severe functional mitral regurgitation (fMR). fMR is one of the most common structural heart valve diseases and affects millions of people worldwide. fMR occurs when an enlarged left ventricle prevents the valve from closing properly, causing blood to flow backwards into the left atrium. Patients with fMR suffer from severe symptoms and face an increased mortality risk.
coramaze stands out in the highly competitive transcatheter valve repair environment with a device design that allows not only a minimally invasive, but truly transfemoral implantation and atraumatic anchoring. The company's novel mitramaze® concept offers fundamental improvements over current concepts and has the potential to overcome present treatment limitations.
The mitramaze® technology is aimed at fMR patients considered unfit for surgery, and has the potential to expand to a broader patient population currently undergoing open heart surgery. coramaze's headquarters are located in Munich, Germany.